All > Fatty Liver > Cirrhosis

BMS-986263 for Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Non-Alcoholic Fatty Liver Disease (NAFLD)BMS-986263 - Drug
Eligibility
21 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new drug to see if it is safe and effective in adults with compensated cirrhosis from NASH.

Eligible Conditions
  • Non-Alcoholic Fatty Liver Disease (NAFLD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Cotadutide
1
CSG452
1
Cohort C: Rencofilstat 225 mg

Study Objectives

1 Primary · 27 Secondary · Reporting Duration: Day 1 to week 12

At 12 weeks
Change from baseline in collagen proportionate area (CPA)
Proportion of participants who achieve ≥ 1 stage improvement in liver fibrosis (NASH CRN Fibrosis Score)
Proportion of participants with ≥ 1 stage improvement in liver fibrosis with no increase of the NAS [NAFLD (Nonalcoholic fatty liver disease) Activity Score] by ≥ 1 point
Proportion of participants with ≥ 1 stage improvement in modified Ishak liver fibrosis score
Proportion of participants with ≥ 2 stage improvement in liver fibrosis score (NASH CRN Fibrosis Score)
Proportion of participants with ≥ 2 stage improvement in modified Ishak liver fibrosis score
Week 12
Plasma Concentrations of ({Bis[2-(tetradecanoyloxy)ethyl] carbamoyl}methyl)-(2-hydroxyethyl) dimethylazanium bromide (HEDC)
Plasma concentrations of components of BMS-986263 for injection
Plasma concentrations of di-retinamide-PEG-di-retinamide (DPD)
Plasma concentrations of lipid component (S104)
Plasma
Up to week 36
Change from baseline in bone mineral density (BMD), as measured by dual-energy x-ray absorptiometry (DXA) scan
Incidence of Adverse Events (AEs)
Incidence of Serious Adverse Events (SAEs)
Incidence of clinically significant changes in clinical laboratory values: Clinical chemistry tests
Incidence of clinically significant changes in clinical laboratory values: Hematology tests
Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests
Electrocardiogram
Electrocardiogram
Electrocardiogram
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcB interval
Electrocardiogram
Incidence of clinically significant changes in physical examination
Incidence of clinically significant changes in vital signs: Blood pressure
Incidence of clinically significant changes in vital signs: Body temperature
Incidence of clinically significant changes in vital signs: Heart rate
Incidence of clinically significant changes in vital signs: Respiratory rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

2
Cotadutide
2
CSG452
2
Cohort C: Rencofilstat 225 mg

Side Effects for

BMS-986263 45 mg QW (Once Weekly)
33%Infusion related reaction
11%Headache
6%Tendonitis
6%Abulia
6%Upper respiratory tract infection
6%Hypothyroidism
6%Vulvovaginal candidiasis
This histogram enumerates side effects from a completed 2019 Phase 2 trial (NCT03420768) in the BMS-986263 45 mg QW (Once Weekly) ARM group. Side effects include: Infusion related reaction with 33%, Headache with 11%, Tendonitis with 6%, Abulia with 6%, Upper respiratory tract infection with 6%.

Trial Design

3 Treatment Groups

Dose B BMS-986263
1 of 3
Dose A BMS-986263
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

270 Total Participants · 3 Treatment Groups

Primary Treatment: BMS-986263 · Has Placebo Group · Phase 2

Dose B BMS-986263
Drug
Experimental Group · 1 Intervention: BMS-986263 · Intervention Types: Drug
Dose A BMS-986263
Drug
Experimental Group · 1 Intervention: BMS-986263 · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986263
2020
Completed Phase 2
~140

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 to week 12

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,496 Previous Clinical Trials
3,930,057 Total Patients Enrolled

Eligibility Criteria

Age 21 - 75 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Iowa100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Local Institution100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top